| Autor: |
Neukam, Karin, Mira, José A., Ruiz-Morales, Josefa, Rivero, Antonio, Collado, Antonio, Torres-Cornejo, Almudena, Merino, Dolores, de los Santos-Gil, Ignacio, Macías, Juan, González-Serrano, Mercedes, Camacho, Angela, Parra-García, Ginés, Pineda, Juan A. |
| Předmět: |
|
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); Nov2011, Vol. 66 Issue 11, p2605-2614, 10p |
| Abstrakt: |
Objectives To compare the frequency of grade 3 or 4 transaminase elevations (TEs) in HIV/hepatitis C virus (HCV) co-infected patients who started a three-antiretroviral drug regimen including efavirenz or a ritonavir-boosted protease inhibitor (PI/r) and the influence of pre-existing significant hepatic fibrosis or cirrhosis. Patients and methods All pre-treated or treatment-naive HIV/HCV co-infected patients who started an antiretroviral regimen including two nucleos(t)ide reverse transcriptase inhibitors along with efavirenz or a PI/r in seven Spanish centres from January 2007 to December 2009 were included in this prospective study. Results Of 262 patients included in this study, 76 (29%) individuals began antiretroviral therapy (ART) including efavirenz and 186 (71%) a PI/r-based combination. The median (interquartile) follow-up was 14.0 (6.2–23.7) months. A total of 20 (7.6%) patients presented grade 3–4 TEs. Four (1.5%) subjects discontinued ART due to this adverse event. Grade 3–4 TEs were observed in 5 (6.6%) subjects receiving efavirenz and 15 (8.1%) treated with PI/r (P = 0.681). Three (6.5%) patients in the efavirenz group with significant fibrosis developed grade 3–4 TEs versus 2 (8.7%) without pre-existing significant fibrosis (P = 0.743). In the PI/r group, the corresponding figures were 10 (8.8%) and 5 (9.3%), respectively (P = 0.931). Conclusions The frequency of grade 3–4 TEs associated with efavirenz-based ART combinations under clinical practice conditions is low and similar to that found in patients receiving PI/r currently used in HIV/HCV co-infected patients. The baseline fibrosis stage does not have an impact on the development of TEs caused by these antiretroviral drugs in this population. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
